AstraZeneca‘s supplemental new drug application for Tagrisso has obtained priority review from the US Food and Drug Administration (FDA) for unresectable Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT).

On receipt of approval, the product will be used to treat patients whose tumours have exon 19 deletions or exon 21 (L858R) mutations.

A decision on the approval of the product under the Prescription Drug User Fee Act is expected in the fourth quarter of 2024.

The sNDA submission is supported by results from the double-blind, randomised, placebo-controlled, multi-centre, global LAURA Phase III trial.

Participants received Tagrisso 80mg once daily oral tablets until experiencing disease progression or unacceptable toxicity, or meeting other discontinuation criteria.

Patients in the placebo group were allowed to switch to Tagrisso upon disease progression.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial involved 216 patients across 145 centres in more than 15 countries.

Tagrisso lowered disease progression or mortality risk by 84% versus placebo, with a median progression-free survival (PFS) of 39.1 months versus 5.6 months for the placebo group.

The PFS benefit was significant across all prespecified subgroups.

While overall survival data showed a favourable trend, it was not mature at the time of analysis.

Safety results and discontinuation rates due to adverse events were consistent with the known profile of Tagrisso, and no new safety concerns were identified.

Tagrisso previously received breakthrough therapy designation from the FDA in this treatment setting.

AstraZeneca oncology research and development executive vice-president Susan Galbraith stated: “Priority review of Tagrisso in this early-stage curative setting is important for patients who currently have no targeted treatments available. We look forward to close collaboration with the FDA on an accelerated path to bring Tagrisso to patients as a potential new standard of care as quickly as possible. 

“Tagrisso continues to serve patients as a backbone therapy in EGFR-mutated lung cancer, extending progression-free survival in the LAURA trial by more than three years and reinforcing the importance of testing for EGFR mutations at the time of diagnosis.”

The latest development comes after AstraZeneca concluded the acquisition of clinical-stage biopharmaceutical company Fusion Pharmaceuticals.